Core Viewpoint - Beijing Union Medical College plans to procure various laboratory instruments for its 2025 educational equipment update project, with a total budget exceeding 274 million RMB [2][3]. Summary by Sections Procurement Overview - The total budget for the 2025 educational equipment update project is over 274 million RMB, specifically 274.18 million RMB [3]. - The project includes the procurement of flow cytometers, gas chromatography-mass spectrometry systems, triple quadrupole liquid chromatography-mass spectrometry systems, PCR instruments, ultra-pure water systems, and digital scanning microscopes [3]. Specific Equipment and Budgets - The budget for the procurement of 14 flow cytometers is set at 45.375 million RMB [3]. - The first batch of equipment procurement has a budget of 10.48 million RMB, including various simulators and systems [4]. - The second batch has a budget of 37.95 million RMB, including high-temperature gel chromatography and high-resolution liquid chromatography-mass spectrometry systems [4]. - The third batch has a budget of 9.45 million RMB, including PCR instruments and digital pathology workstations [5]. - The fourth batch has a budget of 13 million RMB, including high-content microscopy workstations and 3D bioprinting systems [6]. Import Regulations - Some equipment categories do not allow bids from foreign companies, indicating a focus on domestic suppliers for certain instruments [3]. Submission Deadlines - Various submission deadlines for bids are set throughout December 2025, with specific dates provided for each batch of equipment [4][5][6].

Core Viewpoint - The resignation of Mr. Li Ning as Vice President of Shenzhen BGI Genomics Co., Ltd. is due to work arrangement reasons, but he will continue to serve as a director of the company and hold positions in its subsidiaries [2][3]. Summary by Sections Resignation Details - Mr. Li Ning's resignation as Vice President is effective immediately upon the board's receipt of his resignation report, and he will maintain his role as a director [2][3]. - His original term as a senior executive was from June 18, 2024, to June 17, 2027 [3]. Shareholding Information - As of the announcement date, Mr. Li holds 122,600 shares directly and has 1,037,880 shares through the company's second employee stock ownership plan [3]. - His associates do not hold any shares in the company [3]. Compliance and Transition - Mr. Li has completed the necessary work handover in accordance with the company's regulations, ensuring that his resignation will not affect the company's daily operations and management [4]. - The board expressed gratitude for Mr. Li's contributions during his tenure [4].

近日，由中国证券报联合北京证券交易所开展的2025北交所万里行调研活动走进新芝生物。2022年，新 芝生物登陆北交所成为"生命科学仪器第一股"，公司总经理张思远接受中国证券报记者专访时表示，北 交所始终聚焦创新型中小企业的核心需求，不仅为企业注入资金活水，更提升了品牌影响力，助力公司 在产品研发、市场拓展与组织能力上实现全面跃升。 上市三年全链布局 新芝生物是国内较早专注生命科学仪器研发、生产与销售的企业之一，目前已拥有超声波细胞粉碎机、 真空冷冻干燥机、工艺流程温控系统、超声波清洗机、微生物生长曲线分析仪、全自动洗瓶机、基因导 入仪、基因枪等20多条产品线、200多个产品型号，覆盖生物样品处理、分子生物学与药物研究、实验 室自动化与通用设备三大类产品领域。 2022年登陆北交所，成为新芝生物发展的关键里程碑。张思远介绍，上市三年来，公司不仅在超声波处 理、冷冻干燥、恒温控制等传统优势产品上持续迭代，更不断拓展新产品线，推动从实验室设备供应商 向覆盖"实验—中试—量产"全流程的综合服务商转型。 例如，在传统超声领域，公司通过大功率、数字化电源及部件小型化等技术突破，开发出适用于工业级 场景的产品，实现规模化商 ...

● 本报记者 罗京 近日，由中国证券报联合北京证券交易所开展的2025北交所万里行调研活动走进新芝生物。2022年，新 芝生物登陆北交所成为"生命科学仪器第一股"，公司总经理张思远接受中国证券报记者专访时表示，北 交所始终聚焦创新型中小企业的核心需求，不仅为企业注入资金活水，更提升了品牌影响力，助力公司 在产品研发、市场拓展与组织能力上实现全面跃升。 上市三年 全链布局 自主攻坚 逐步出海 新芝生物是国内较早专注生命科学仪器研发、生产与销售的企业之一，目前已拥有超声波细胞粉碎机、 真空冷冻干燥机、工艺流程温控系统、超声波清洗机、微生物生长曲线分析仪、全自动洗瓶机、基因导 入仪、基因枪等20多条产品线、200多个产品型号，覆盖生物样品处理、分子生物学与药物研究、实验 室自动化与通用设备三大类产品领域。 2022年登陆北交所，成为新芝生物发展的关键里程碑。张思远介绍，上市三年来，公司不仅在超声波处 理、冷冻干燥、恒温控制等传统优势产品上持续迭代，更不断拓展新产品线，推动从实验室设备供应商 向覆盖"实验—中试—量产"全流程的综合服务商转型。 例如，在传统超声领域，公司通过大功率、数字化电源及部件小型化等技术突破，开 ...

● 本报记者罗京 近日，由中国证券报联合北京证券交易所开展的2025北交所万里行调研活动走进新芝生物。2022年，新 芝生物登陆北交所成为"生命科学仪器第一股"，公司总经理张思远接受中国证券报记者专访时表示，北 交所始终聚焦创新型中小企业的核心需求，不仅为企业注入资金活水，更提升了品牌影响力，助力公司 在产品研发、市场拓展与组织能力上实现全面跃升。 上市三年全链布局 新芝生物是国内较早专注生命科学仪器研发、生产与销售的企业之一，目前已拥有超声波细胞粉碎机、 真空冷冻干燥机、工艺流程温控系统、超声波清洗机、微生物生长曲线分析仪、全自动洗瓶机、基因导 入仪、基因枪等20多条产品线、200多个产品型号，覆盖生物样品处理、分子生物学与药物研究、实验 室自动化与通用设备三大类产品领域。 2022年登陆北交所，成为新芝生物发展的关键里程碑。张思远介绍，上市三年来，公司不仅在超声波处 理、冷冻干燥、恒温控制等传统优势产品上持续迭代，更不断拓展新产品线，推动从实验室设备供应商 向覆盖"实验—中试—量产"全流程的综合服务商转型。 例如，在传统超声领域，公司通过大功率、数字化电源及部件小型化等技术突破，开发出适用于工业级 场景的 ...

Core Insights - The article emphasizes the importance of independent innovation and self-reliance in high-end scientific instruments, particularly in the context of China's "14th Five-Year Plan" which promotes technological self-sufficiency and the cultivation of emerging industries [1][3][11] - Haier Biomedical has achieved a significant breakthrough by launching a super-speed centrifuge that exceeds 100,000 RPM, marking a transition from reliance on imports to self-sufficiency in high-end life science instruments [1][5][9] Industry Overview - The demand for ultra-speed centrifuges is increasing due to advancements in cell therapy, vaccine development, and pharmaceutical processes, necessitating higher efficiency and precision in laboratory operations [3][5] - Despite improvements in domestic high-speed centrifuges, the high-end market remains dominated by international brands, with domestic products holding only 38% of the market share as of 2025 [3][5] Company Developments - Haier Biomedical's new centrifuge not only meets international standards in terms of stability and data security but also offers customizable data management features, enhancing safety and compliance for laboratory personnel [5][6] - The company is transitioning from being a mere equipment supplier to a service provider, focusing on creating intelligent laboratory solutions that cater to the specific needs of researchers [6][10] Product Innovations - In addition to the super-speed centrifuge, Haier Biomedical showcased several advanced products at the China International Import Expo, including a rapid freezing instrument and an automated cell expansion system, which are designed to meet the growing demands of life science research [7][8] - The rapid freezing instrument can achieve cooling rates of 10,000°C/s, preserving sample integrity for high-resolution structural analysis [7] Market Potential - The global life science tools market is projected to grow from approximately $161.57 billion in 2023 to over $330.69 billion by 2030, with a compound annual growth rate of 10.8% [11] - As the global pharmaceutical R&D spending increases, the demand for high-quality laboratory instruments and tools is expected to rise significantly, presenting opportunities for companies like Haier Biomedical to expand their market presence [10][11]

Core Insights - Shenzhen BGI Genomics Co., Ltd. has entered into a licensing agreement with Swiss biotechnology company SwissRocketsAG for the CoolMPS sequencing technology, marking a significant step in the internationalization of Chinese life science instruments [1][2] - The agreement will generate a minimum of $120 million in licensing fees for BGI, including a non-refundable upfront payment of $20 million and milestone payments of $20 million, along with a tiered royalty based on net sales of licensed products [1][2] Company Developments - BGI's third-quarter report for 2025 shows a revenue of 755 million yuan, a year-on-year increase of 14.45%, and a successful turnaround to profitability [2] - The company has established a global presence, covering over 110 countries and serving more than 3,560 users as of June 30, 2025 [2] - The collaboration with SwissRockets is expected to enhance BGI's international competitiveness and provide a sustainable global path for technology licensing and revenue sharing [2]

Core Viewpoint - The company reported strong performance in Q3 2025, with revenue, profit, and cash flow exceeding market expectations, driven by robust growth in the bioprocessing segment and better-than-expected revenue from Cepheid's respiratory business [2][3]. Financial Performance - Total revenue for Q3 reached $6.1 billion, a 4.5% increase from $5.798 billion in Q3 2024; Non-GAAP core revenue grew by 3.0% [3]. - Net profit attributable to common shareholders was $908 million, up 11.0% year-over-year, and a significant 63.6% increase from $555 million in Q2 2025; diluted EPS (GAAP) was $1.27, a 13.4% increase from $1.12 [3]. - Operating cash flow was $1.662 billion, a 9.8% year-over-year increase; Non-GAAP free cash flow reached $1.37 billion, up 11.8% from $1.226 billion [3]. Cost and Profit Structure - Q3 sales cost was $2.53 billion, a 5.6% increase, which was lower than revenue growth; gross margin was 58.2%, remaining stable compared to 58.7% in the previous year [4]. - Selling, general, and administrative expenses decreased by 3.4% to $1.991 billion, while R&D expenses slightly declined by 1.3% to $378 million, indicating effective cost control [4]. Segment Performance - Biotech segment grew by 9.0%, driven by strong demand in bioprocessing; Life Sciences segment saw a modest 0.5% growth, impacted by currency fluctuations; Diagnostics segment revenue increased by 4.0%, supported by Cepheid's respiratory business [6]. - Year-to-date revenue reached $17.73 billion, a 2.5% increase compared to the same period in 2024; Biotech segment led with a 7.5% revenue growth, while Life Sciences segment experienced a 1.0% decline [6]. Full-Year Outlook - The company maintains its full-year Non-GAAP diluted EPS guidance in the range of $7.70 to $7.80, expecting low single-digit growth in Non-GAAP core revenue [7]. - For Q4, core revenue is anticipated to achieve low single-digit growth, with the Biotech segment expected to grow around 5% and Life Sciences segment projected to decline slightly [7]. Management Insights - The CEO highlighted the encouraging Q3 performance, attributing it to effective execution of the Danaher Business System and ongoing growth in bioprocessing, alongside Cepheid's strong revenue [9]. - The company continues to focus on innovation, enhancing operational efficiency, and addressing key challenges in global healthcare [9].

Core Viewpoint - The company reported a revenue of 755 million yuan for Q3 2025, marking a year-on-year increase of 14.45%, but incurred a net loss attributable to shareholders of 15.9983 million yuan [1] Financial Performance - For the first three quarters, the company achieved a revenue of 1.869 billion yuan, which represents a slight decline of 0.01% year-on-year [1] - The net loss attributable to shareholders for the first three quarters was 120 million yuan, with a basic earnings per share of -0.29 yuan [1] - The basic earnings per share for Q3 2025 was reported at -0.04 yuan [1]

Core Insights - The HICOOL 2025 Global Entrepreneur Summit was held in Beijing from October 16 to 18, showcasing the role of basic science in driving industrial development, with a focus on innovative products from various research institutions and enterprises [1][2] Group 1: Technological Innovations - The exhibition featured 14 cutting-edge products from 10 research institutions and innovative companies, covering fields such as high-end sensors, life sciences, new energy materials, and artificial intelligence [1] - The "Jier" intelligent breeding robot, developed by the Chinese Academy of Sciences, reduces traditional breeding cycles from 5 years to 1 year, providing crucial support for food security and agricultural modernization in China [1] - The "ELI-TriScope" imaging system, developed by the Chinese Academy of Sciences, has achieved a sample preparation success rate of over 90%, recognized as one of the top original technologies in life sciences by Nature magazine [2] - The self-powered landslide monitoring sensor from the Chinese Academy of Sciences can operate without electricity, utilizing the natural movement of the mountain, which is expected to enhance early warning systems for geological disasters [2] - The "Xuanhuang Health Detection Device" integrates traditional Chinese medicine with modern AI, capable of assessing the health status of various body systems in just 3 minutes [2] Group 2: Infrastructure and Policy Support - The exhibition also highlighted major technological infrastructure clusters, open technology platforms, high-quality industrial spaces, and policies to attract young talent for innovation and entrepreneurship [3] - Huairou Science City has established 37 technological facility platforms, with 4 large scientific devices operational and 16 platforms open for global sharing, providing over 1.51 million hours of service [3] - The establishment of the International Advanced Laser Alliance aims to position Huairou Science City as a global innovation hub for the laser industry, facilitating collaboration between academia, industry, and research [4]